Effect of sitagliptin on the working memory and reference memory in type 2 diabetic sprague-dawley rats: Possible role of adiponectin receptors 1

Journal of Physiology and Pharmacology

Volumn 64, Issue 5, 2013, Pages 613-623

  Sakr, H F ^a,b  

^a MANSOURA UNIVERSITY   (Egypt)

^b KING KHALID UNIVERSITY   (Saudi Arabia)

Author keywords

Acetylcholine; Adiponectin; Adiponectin receptors 1; Dementia; Diabetes mellitus type 2; Glucose; Insulin; Sitagliptin; Working memory

Indexed keywords

ACETYLCHOLINE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; CHOLESTEROL; COMPLEMENTARY DNA; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; SITAGLIPTIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENIC INDEX; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HOLEBOARD MEMORY TEST; HOMEOSTASIS; HOMEOSTASIS MODEL OF ASSESSMENT INSULIN RESISTANCE INDEX; HORMONE BLOOD LEVEL; HYPOTHALAMUS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; NEUROLOGIC EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PSYCHOMETRY; RAT; RATING SCALE; REFERENCE MEMORY; RNA ISOLATION; SPRAGUE DAWLEY RAT; TRIACYLGLYCEROL BLOOD LEVEL; WORKING MEMORY;

ACETYLCHOLINE; ADIPONECTIN; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; HYPOGLYCEMIC AGENTS; HYPOTHALAMUS; INSULIN; LIPIDS; MALE; MEMORY; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADIPONECTIN; TRIAZOLES;

EID: 84888235042     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Zhao WQ, De Felice F G, Fernandez S, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 2008; 22: 246-260.
2. Munshi M, Grande L, Hayes M, et al. Cognitive dysfunction is associated with poor diabetes control in older adults. Diabetes Care 2006; 29: 1794-1799.
3. van Harten B, de Leeuw FE, Weinstein HC, Scheltens P, Biessels GJ. Brain imaging in patients with diabetes. A systematic review. Diabetes Care 2006; 29: 2539-2548.
4. Tiehuis AM, van der Graaf Y, Visseren FL, et al. Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease. Stroke 2008; 39: 1600-1603.
5. Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001; 24: 1416-1421.
6. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140: 5356-5363.
7. Deutsch JA. The cholinergic synapse and the site of memory. Science 1971; 174: 788-794.
8. Dawson GR, Heyes CM, Iversen SD. Pharmacological mechanisms and animal models of cognition. Behav Pharmacol 1992; 3: 286-297.
9. Croxson PL, Browning PG, Gaffan D, Baxter MG. Acetylcholine facilitates recovery of episodic memory after brain damage. J Neurosci 2012; 32: 13787-13795.
10. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Tren ds Endocrinol Metab 2002; 13: 84-89.
11. Gil-Campos M, Canete R, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004; 23: 963-974.
12. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-779.
13. Yamauchi T, Nio Y, Maki T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and\metabolic actions. Nat Med 2007; 13: 332-339.
14. Kos K, Harte AL, da Silva NF, et al. Adiponectin and resistin in human cerebrospinal fluid and expression of adiponectin receptors in the human hypothalamus. J Clin Endocrinol Metab 2007; 92: 1129-1136.
15. Kubota N, Yano W, Kubota T, et al. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab 2007; 6: 55-68.
16. Coope A, Milanski M, Araujo P, et al. AdipoR1 mediates the anorexigenic and insulin/leptin-like actions ofadiponectine in the hypothalamus. FEBS Lett 2008; 582: 1471-1476.
17. Jung TW, Lee JY, Shim WS, Kang ES, Kim JS, et al. Adiponectin protects human neuroblastoma SH-SY5Y cells against MPP+-induced cytotoxicity. Biochem Biophys Res Commun 2006; 343: 564-570.
18. Jeon BT, Shin HJ, Kim JB, et al. Adiponectin protects hippocampal neurons against kainic acid-induced excitotoxicity. Brain Res Rev 2009; 61: 81-88.
19. Chen B, Liao WQ, Xu N, et al. Adiponectin protects against cerebral ischemia-reperfusion injury through anti-inflammatory action. Brain Res 2009; 1273: 129-137.
20. Psilopanagioti A, Papadaki H, Kranioti EF, Alexandrides TK, Varakis JN. Expression of adiponectin and adiponectin receptor in human pituitary gland and brain. Neuroendocrinology 2009; 89: 38-47.
21. Vawter M P, Van Ree JM. Hole board food search task in rats: effects of hole depths and food deprivation. Physiol Behav 1989; 45: 891-895.
22. Mega C, de Lemos ET, Vala H, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (zucker diabetic fatty rat) Exp Diab Res 2011; 2011: 162092. doi: 10.1155/2011/162092.
23. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 1998; 112: 1199-1208.
24. Trinder P. Determination of blood glucose using 4-amino phenazone as oxygen acceptor. J Clin Pathol 1969; 22: 246.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher D F, Turner RC. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
26. Friedwald, WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
27. Maebuchi M, Machidori M, Urade R, Ogawa T, Moriyama T. Low resistin levels in adipose tissues and serum in high-fat fed mice and genetically obese mice: development of an ELISA system for quantification of resistin. Arch Biochem Biophys 2003; 416: 164-170.
28. Lopez I P, Milagro FI, Marti A, Moreno-Aliaga MJ, Martinez JA, De Miguel C. High-fat feeding period affects gene expression in rat white adipose tissue. Mol Cell Biochem 2005; 275: 109-115.
29. Strachan MW, Reynolds RM, Frier BM, Mitchell RJ, Price JF. The relationship between type 2 diabetes and dementia. Br Med Bull 2008; 88: 131-146.
30. Moreira T, Malec E, Ostenson C G, Efendic S, Liljequist S. Diabetic type II Goto-Kakizaki rats show progressively decreasing exploratory activity and learning impairments in fixed and progressive ratios of a lever-press task. Behav Brain Res 2007; 180: 28-41.
31. Stasiak A, Mussur M, Unzeta M, Lazewska D, Kiec-Kononowicz K, Fogel WA. The central histamine level in rat model of vascular dementia. J Physiol Pharmacol 2011; 62: 549-558.
32. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 1: CD004395. 2004.
33. Irie F, Fitzpatrick A, Lopez O, et al. Enhanced risk for Alzheimer disease in persons with type 2 diabetes and apoE4. Arch Neurol 2008; 65: 89-93.
34. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 1999; 26: 439-451.
35. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-10703.
36. Mori Y, Ide T, Murakami K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
37. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
38. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
39. Kumada M, Kihara S, Sumitsuji S, et al. Osaka CAD Study Group. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89.
40. Ouchi N, Ohishi M, Kihara S, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231-234.
41. Trujillo ME, Scherer PE, Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257: 167-175.
42. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve-and fifty two-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874-2880.
43. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894.
44. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005; 28: 1936-1940.
45. Lim S, Choi SH, Shin H, et al. Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. PLoS One 2012; 7: e35007.
46. Suzuki K, Watanabe K, Suzuki T, et al. Sitagliptin improves vascular endothelial function in Japanese type 2 diabetes patients without cardiovascular disease JDM 2012; 2: 338-345.
47. Al-Hashim F, Ibriahim I, Bastawy N, et al. Effect of insulin on adiponectin and adiponectin receptor-1 expression in rats with streptozocin induced type 2 diabetes. J Health Sci 2011; 57: 334-340.
48. Kuminski CM, McTernan PG, Schraw T, et al. Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum. Diabetologia 2007; 50: 634-642.
49. Norsted E, Gomuc B, Meister B. Protein components of the blood-brain barrier (BBB) in the mediobasal hypothalamus. J Chem Neuroanat 2008; 36: 107-121.
50. Zhang D, Guo M, Zhang W, Lu XY. Adiponectin stimulates proliferation of adult hippocampal neural stem/progenitor cells through activation of the p38MAPK/GSK-3b/b-catenin signaling cascade J Biol Chem 2011; 286: 44913-4420.
51. Perry T, Haughey NJ, Mattson M P, et al. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 2002; 302: 881-888.
52. Perry T, Lahiri DK, Chen D, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002; 300: 958-966.
53. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9: 1173-1179.
54. Perry T, Greig NH. The glucagon-like peptides: a double-edged therapeutic sword? Trends Pharmacol Sci 2003; 24: 377-383.
55. Abbas T, Faivre E, Holscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res 2009; 205: 265-271.
56. Javelot H, Messaoudi M, Garnier S, Rougeot C. Human opiorphin is a naturally occurring antidepressant acting selectively on enkephalin-dependent delta-opioid pathways. J Physiol Pharmacol 2010; 61: 355-362.
57. Ciecko-Michalska I, Wojcik J, Wyczesany M, et al. Cognitive evoked response potentials in patients with liver cirrhosis without diagnosis of minimal or overt hepatic encephalopathy. A pilot study. J Physiol Pharmacol 2012; 63: 271-276.